| Drug Name |
Hydromorphone |
| Drug ID |
BADD_D01096 |
| Description |
Hydromorphone is a pure opioid,[A176468] a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound.[A176471] Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential).[A176495]
The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795] |
| Indications and Usage |
For the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N02AA03 |
| DrugBank ID |
DB00327
|
| KEGG ID |
D08047
|
| MeSH ID |
D004091
|
| PubChem ID |
5284570
|
| TTD Drug ID |
D04JHN
|
| NDC Product Code |
Not Available |
| Synonyms |
Hydromorphone | Dihydromorphinone | Hydromorphon | Palladone | Laudacon | Dilaudid | Hydromorphone Hydrochloride |
